Slideshow
Author(s):
These apps are designed to improve treatment adherence, language skills, symptom tracking, communication, and other helpful functions.
Anti-Tau Agent E2814 Shows Impact on Early and Late Tau Biomarkers, Further Supporting Development
Episode 122: RNA Therapeutics, Mivelsiran, and Treating Alzheimer Disease
NeurologyLive® Friday 5 — October 25, 2024
Special Episode: FDA Approves Donanemab for Early Symptomatic Alzheimer Disease
How America's Neurological Care Crisis is Reshaping Medicare and What That Means for You
NeurologyLive® Friday 5 — October 18, 2024